Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
By A. Ford, W. Sandborn, K. Khan, S. Hanauer, N. Talley, P. Moayyedi. American Journal of Gastroenterology, 2011
623 citations recorded by the source corpus.
Subfields: Epidemiology, Genetics
View Paper: https://www.semanticscholar.org/paper/8fd2962e18af076223fd19838ea2b55d8a756c52
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Genetics
Citations in the corpus
- ACG Clinical Guideline: Ulcerative Colitis in Adults (2019, background): “In patients with moderately to severely active UC who have responded to anti-TNF therapy during induction dosing, antiTNF agents are superior to placebo in maintaining remission (127).”
- Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management (2016, background): “The incidence of PNR varies between clinical trial and clinical practice from 10–20% to 13–30%.(2,3,5) Several factors seem to negatively influence the risk to develop PNR such as disease longer than 2 years, small bowel involvement, smoking, C reactive protein, and also genetic mutations such as FA”
- ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. (2019, background): “The pooled RR of any AEs was not significantly different between ustekinumab and vedolizumab [64.2% vs 56.2%; RR: 1.00; 95% CI: 0.82–1.23].”